Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Schering-Plough 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Schering-Plough 4Q

Sales of Remicade were $491 million in the quarter (+8%) and $2.1 billion for the year (+28%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schering-Plough

4Q Revenues: $4.3 billion (+17%)

4Q Earnings: $480 million (loss of $3.3 billion in 4Q07)

FY Revenues: $18.5 billion (+46%)

FY Earnings: $1.6 billion (loss of $1.6 billion FY07)

Comments: Sales of Remicade were $491 million in the quarter (+8%) and $2.1 billion for the year (+28%). Sales of Temodar were up 4% to $242 million in the quarter and $1.0 billion for the year (+16%). Global sales of Nasonex were $280 million in the quarter (+3%) and $1.2 billion for the year (+6%). Sales of Pegintron were $225 million in the quarter (-6%) and flat at $914 million for the year. Sales of Clarinex in the quarter were $160 million (-8%) and $790 million for the year (-1%). Vytorin and Zetia sales totaled $1.1 billion in the quarter (-26%). SP does not record these sales directly, as the venture is accounted for under the equity method of its cholesterol JV with Merck. R&D expenses were $850 million in the quarter (flat) and $3.5 billion for the year (+21%), which includes $21 million and $197 million, respectively, related to upfront R&D payments. Sales for the quarter and year include Organon BioSciences (OBS) products, representing $1.3 billion and $5.4 billion, respectively. Results in 2007 were impacted by $3.8 billion of acquired in-process R&D charges related to the purchase of OBS.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters